HPVIQ-PedOnc Intervention in Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Hematopoietic Malignancies
Solid Tumor
9 Years and older, Male and Female
XUAB2035 (primary)
NCI-2021-00009
Summary
This clinical trial evaluates the impact of implementing an evidence-based, provider-focused intervention called HPVIQ-PedOnc on human papillomavirus (HPV) vaccination rates in young cancer survivors. HPVIQ-PedOnc is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPVIQ-PedOnc intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context. HPVIQ-PedOnc may increase the uptake of the HPV vaccine and ultimately decrease the risk of developing HPV-related cancers in young cancer survivors.
Objectives
PRIMARY OBJECTIVE:
I. Among childhood cancer survivors 9-17 year (y) and >= 1y post-completion of cancer therapy (targeted age/time frame for vaccination) who are returning for follow-up care (in-person or via telehealth) across 6 geographically-diverse pediatric oncology clinics: Conduct a cluster-randomized, stepped wedge trial to evaluate the effectiveness of HPVIQPedOnc, in improving HPV vaccine initiation rates 1y post-intervention.
SECONDARY OBJECTIVES:
I. Ascertain healthcare provider perspectives regarding feasibility, acceptability, and appropriateness of HPVIQ-PedOnc in the pediatric oncology setting.
II. Assess intervention fidelity.
III. Estimate change in healthcare provider HPV vaccine-related knowledge and practices.
EXPLORATORY OBJECTIVE:
I. Estimate the effect of HPVIQ-PedOnc on: series completion; and ongoing improvement in initiation rates in the years subsequent to HPVIQ-PedOnc implementation (sustainability).
OUTLINE: Sites are randomized to 1 of 2 groups.
GROUP I (EARLY INTERVENTION [SITES A, B, C]): During Year 1, sites proceed with usual care and measure HPV vaccination rates of the targeted population using state vaccine registry data accessible via the electronic medical record (EMR) at their site. In Years 2 and 3, sites implement HPVIQ-PedOnc. In Year 4, sustainability of HPVIQ-PedOnc is assessed at the sites.
GROUP II (DELAYED INTERVENTION [SITES D, E, F]): During Years 1 and 2, sites proceed with usual care and measure HPV vaccination rates of the targeted population using state vaccine registry data accessible via the EMR at their site. In Year 3, sites implement HPVIQ-PedOnc. In Year 4, sustainability of HPVIQ-PedOnc is assessed at the sites.
Eligibility
- HEALTHCARE PROVIDERS: Healthcare providers (physicians, advanced practice providers) in the pediatric oncology clinics at the participating sites: caring for cancer survivors seen in the targeted clinic (in-person or via telehealth) who are age 9-17y, >= 1y off-therapy, and residing in state where clinic is located; licensed to order vaccines; willing to complete surveys and/or interviews
- CHILDHOOD CANCER SURVIVORS: Childhood cancer survivors 9-17y of age and >= 1y following completion of cancer therapy who receive follow-up care (in person or via telehealth) in the pediatric oncology clinic at a participating site
- CHILDHOOD CANCER SURVIVORS: Resides in the state where the clinic is located
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.